PMID- 25418192
OWN - NLM
STAT- MEDLINE
DCOM- 20150602
LR  - 20181202
IS  - 1000-467X (Print)
IS  - 1944-446X (Electronic)
IS  - 1944-446X (Linking)
VI  - 33
IP  - 12
DP  - 2014 Dec
TI  - Investigation of osteosarcoma genomics and its impact on targeted therapy: an 
      international collaboration to conquer human osteosarcoma.
PG  - 575-80
LID - 10.5732/cjc.014.10209 [doi]
AB  - Osteosarcoma is a genetically unstable malignancy that most frequently occurs in 
      children and young adults. The lack of progress in managing this devastating 
      disease in the clinic has prompted international researchers to collaborate to 
      profile key genomic alterations that define osteosarcoma. A team of researchers 
      and clinicians from China, Finland, and the United States investigated human 
      osteosarcoma by integrating transcriptome sequencing (RNA-seq), high-density 
      genome-wide array comparative genomic hybridization (aCGH), fluorescence in situ 
      hybridization (FISH), reverse transcription-polymerase chain reaction (RT-PCR), 
      Sanger sequencing, cell culture, and molecular biological approaches. Systematic 
      analysis of genetic/genomic alterations and further functional studies have led 
      to several important findings, including novel rearrangement hotspots, 
      osteosarcoma-specific LRP1-SNRNP25 and KCNMB4-CCND3 fusion genes, VEGF and Wnt 
      signaling pathway alterations, deletion of the WWOX gene, and amplification of 
      the APEX1 and RUNX2 genes. Importantly, these genetic events associate 
      significantly with pathogenesis, prognosis, progression, and therapeutic activity 
      in osteosarcoma, suggesting their potential impact on improved managements of 
      human osteosarcoma. This international initiative provides opportunities for 
      developing new treatment modalities to conquer osteosarcoma.
FAU - Yang, Ji-Long
AU  - Yang JL
AD  - Departments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer 
      Institute & Hospital, Tianjin 300060, P. R. China. yangjilong@tjmuch.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141121
PL  - England
TA  - Chin J Cancer
JT  - Chinese journal of cancer
JID - 101498232
RN  - EC 4.2.99.18 (APEX1 protein, human)
RN  - EC 4.2.99.18 (DNA-(Apurinic or Apyrimidinic Site) Lyase)
SB  - IM
MH  - Adult
MH  - Bone Neoplasms
MH  - Child
MH  - China
MH  - Comparative Genomic Hybridization
MH  - DNA-(Apurinic or Apyrimidinic Site) Lyase
MH  - Genomics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Molecular Targeted Therapy
MH  - Osteosarcoma/*genetics/*therapy
MH  - Prognosis
MH  - Wnt Signaling Pathway
MH  - Young Adult
PMC - PMC4308652
EDAT- 2014/11/25 06:00
MHDA- 2015/06/03 06:00
PMCR- 2014/12/01
CRDT- 2014/11/25 06:00
PHST- 2014/11/25 06:00 [entrez]
PHST- 2014/11/25 06:00 [pubmed]
PHST- 2015/06/03 06:00 [medline]
PHST- 2014/12/01 00:00 [pmc-release]
AID - cjc.014.10209 [pii]
AID - cjc-33-12-575 [pii]
AID - 10.5732/cjc.014.10209 [doi]
PST - ppublish
SO  - Chin J Cancer. 2014 Dec;33(12):575-80. doi: 10.5732/cjc.014.10209. Epub 2014 Nov 
      21.